NO20081847L - Fremgangsmate for a forbedre kognitiv funksjon - Google Patents

Fremgangsmate for a forbedre kognitiv funksjon

Info

Publication number: NO20081847L
Authority: NO; Norway
Prior art keywords: cognitive function; subject; procedures; improving cognitive; homozygous
Prior art date: 2005-09-22

Application number

NO20081847A

Other languages

English (en)

Norwegian (no)

Inventor

Allen D Roses

Ann M Saunders

Original Assignee

Sb Pharmco Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2008-04-16

Publication date

2008-06-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081847(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-16 Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc

2008-06-18 Publication of NO20081847L publication Critical patent/NO20081847L/no

Links

238000000034 method Methods 0.000 title abstract 3
230000003920 cognitive function Effects 0.000 title abstract 2
108700028369 Alleles Proteins 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)

NO20081847A 2005-09-22 2008-04-16 Fremgangsmate for a forbedre kognitiv funksjon NO20081847L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US71935305P	2005-09-22	2005-09-22
US72737705P	2005-10-17	2005-10-17
PCT/US2006/036603 WO2007038115A2 (fr)	2005-09-22	2006-09-20	Procede d'amelioration de la fonction cognitive

Publications (1)

Publication Number	Publication Date
NO20081847L true NO20081847L (no)	2008-06-18

Family

ID=37876831

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20081847A NO20081847L (no)	2005-09-22	2008-04-16	Fremgangsmate for a forbedre kognitiv funksjon
NO20081843A NO20081843L (no)	2005-09-22	2008-04-16	Farmasoytisk sammensetning for forbedret kognitiv funksjon

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20081843A NO20081843L (no)	2005-09-22	2008-04-16	Farmasoytisk sammensetning for forbedret kognitiv funksjon

Country Status (16)

Country	Link
US (2)	US20080226719A1 (fr)
EP (2)	EP1926488A2 (fr)
JP (2)	JP2009508960A (fr)
KR (2)	KR20080056731A (fr)
AR (2)	AR056527A1 (fr)
AU (2)	AU2006295007A1 (fr)
BR (2)	BRPI0616100A2 (fr)
CA (2)	CA2623204A1 (fr)
CR (2)	CR9849A (fr)
EA (2)	EA200800880A1 (fr)
IL (2)	IL190224A0 (fr)
MA (2)	MA29871B1 (fr)
NO (2)	NO20081847L (fr)
PE (2)	PE20070618A1 (fr)
TW (2)	TW200803851A (fr)
WO (2)	WO2007038112A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008036678A2 (fr) *	2006-09-19	2008-03-27	Braincells, Inc.	Modulation induite par ppar de la neurogenèse
IL187159A0 (en) *	2007-07-03	2009-02-11	Gur Megiddo	Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (fr) *	2007-10-05	2009-04-09	Merz Pharma Gmbh & Co. Kgaa	Thérapie de combinaison utilisant la mémantine et les glitazones
EP2085120A1 (fr) *	2008-02-01	2009-08-05	Merz Pharma GmbH & Co. KGaA	Utilisation de substances pour le traitement d'une déficience de récepteur d'insuline périphérique ou central et résistance à l'insuline
US8846315B2 (en)	2008-08-12	2014-09-30	Zinfandel Pharmaceuticals, Inc.	Disease risk factors and methods of use
DK2324126T3 (da)	2008-08-12	2014-06-16	Zinfandel Pharmaceuticals Inc	FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
WO2010068750A2 (fr) *	2008-12-11	2010-06-17	Board Of Trustees Of Leland Stanford Junior University	Compositions et procédé pour le traitement des perturbations de l'humeur et des déficiences cognitives
BRPI1015231A2 (pt) *	2009-06-25	2018-02-20	Alcobra Ltd	método para tratamento, suavização de sintomas, alívio, melhoria e prevenção de uma doença, distúrbio ou condição cognitiva
US20100178307A1 (en) *	2010-01-13	2010-07-15	Jianye Wen	Transdermal anti-dementia active agent formulations and methods for using the same
US20130267560A1 (en) *	2010-10-22	2013-10-10	Cadila Healthcare Limited	Sustained release pharmaceutical compositions of donepezil
WO2012096680A1 (fr) *	2011-01-10	2012-07-19	Zinfandel Pharmaceuticals, Inc.	Facteurs de risque pour une maladie et leurs procédés d'utilisation
KR20180050420A (ko)	2011-01-10	2018-05-14	진판델 파마슈티컬스 인코포레이티드	알츠하이머 병 치료를 위한 방법 및 약품
AR088398A1 (es)	2011-10-21	2014-05-28	Takeda Pharmaceutical	Preparacion de liberacion sostenida
CA2853100A1 (fr) *	2011-10-24	2013-05-02	Intellect Neurosciences, Inc.	Compositions et methodes de traitement de proteinopathies
JPWO2014171542A1 (ja) *	2013-04-19	2017-02-23	武田薬品工業株式会社	放出制御製剤
CA3032036A1 (fr) *	2016-07-26	2018-02-01	Ausio Pharmaceuticals, Llc	Methodes de diagnostic et de traitement de la maladie d'alzheimer par s-equol
US20180153859A1 (en) *	2016-12-02	2018-06-07	T3D Therapeutics, Inc.	Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) *	2017-05-31	2020-08-06	주식회사 대웅제약	방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224918B1 (ko)	2018-03-20	2021-03-09	(주)인벤티지랩	도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69333461T2 (de) *	1992-10-13	2005-03-24	Duke University	VERFAHREN ZUM nachweis der Alzheimer Krankheit
US6191154B1 (en) *	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
ATE476978T1 (de) *	1998-12-17	2010-08-15	Mindset Biopharmaceuticals Usa	Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
WO2005074917A1 (fr) *	2004-01-30	2005-08-18	Axonyx, Inc.	Methodes de traitement de complications du diabete

2006
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/fr active Application Filing
- 2006-09-20 EP EP06815011A patent/EP1926488A2/fr not_active Withdrawn
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/fr active Application Filing
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 EP EP06803887A patent/EP1940403A2/fr not_active Withdrawn
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 CA CA002623204A patent/CA2623204A1/fr not_active Abandoned
- 2006-09-20 CA CA002623210A patent/CA2623210A1/fr not_active Abandoned
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
2008
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2623210A1 (fr)	2007-04-05
JP2009508959A (ja)	2009-03-05
JP2009508960A (ja)	2009-03-05
IL190217A0 (en)	2008-11-03
AU2006295010A1 (en)	2007-04-05
BRPI0616100A2 (pt)	2011-06-07
AU2006295007A1 (en)	2007-04-05
AR056527A1 (es)	2007-10-10
PE20070618A1 (es)	2007-07-04
CA2623204A1 (fr)	2007-04-05
CR9849A (es)	2008-05-21
MA29871B1 (fr)	2008-10-03
BRPI0616192A2 (pt)	2011-06-14
AR055649A1 (es)	2007-08-29
US20080262047A1 (en)	2008-10-23
WO2007038112A3 (fr)	2007-12-06
WO2007038115A3 (fr)	2007-12-13
CR9848A (es)	2008-06-18
EP1926488A2 (fr)	2008-06-04
WO2007038112A2 (fr)	2007-04-05
KR20080056731A (ko)	2008-06-23
KR20080058413A (ko)	2008-06-25
MA29872B1 (fr)	2008-10-03
EA200800879A1 (ru)	2008-10-30
NO20081843L (no)	2008-06-16
TW200803851A (en)	2008-01-16
IL190224A0 (en)	2008-11-03
PE20070976A1 (es)	2007-12-05
EA200800880A1 (ru)	2009-02-27
US20080226719A1 (en)	2008-09-18
EP1940403A2 (fr)	2008-07-09
TW200803896A (en)	2008-01-16
WO2007038115A2 (fr)	2007-04-05

Legal Events

Date	Code	Title	Description
2011-05-09	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20081847L (no)	2008-06-18	Fremgangsmate for a forbedre kognitiv funksjon
Kezic et al.	2011	Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity
Velez et al.	2007	Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes
NO20090156L (no)	2009-03-27	Humanisert antistoff
Azizi et al.	2012	Comparison of salivary and plasma antioxidant levels in lichen planus patients and healthy subjects
NO20063300L (no)	2006-09-14	Fremgangsmater for behandling av akutt inflammasjon i dyr med p38 MAP kinaseinhibitorer
NO20061239L (no)	2006-06-08	Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
NO20082673L (no)	2008-07-23	Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20074332L (no)	2007-10-17	Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
NO20044562L (no)	2004-11-15	Fremgangsmater for behandling av tarmslyng
NO20065560L (no)	2006-12-01	Anvendelse av IL-17-uttrykking for a forutsi hudinflammasjon, fremgangsmater for behandling.
AU2008304205A8 (en)	2014-08-28	Methods and systems for genomic analysis using ancestral data
NO20091926L (no)	2009-07-17	Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20075821L (no)	2008-01-07	Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20064610L (no)	2006-12-04	Identifikasjon av selv- og ikke selvantigener implisert i autoimmune sykdommer
DE602004014117D1 (de)	2008-07-10	Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE548025T1 (de)	2012-03-15	Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung
NO20064325L (no)	2006-11-22	Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20070592L (no)	2007-03-27	Fremgangsmate for diagnostisering av prodromale former av sykdommer som er forbundet med amyloid avleiring.
NO20082894L (no)	2008-09-30	Metode for behandling av kognitiv dysfunksjon
ATE452884T1 (de)	2010-01-15	Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
NO20084993L (no)	2008-11-28	Forklaring, metoder, og prover for identifisering av nye smakscelle-gener og saltsmak-reseptor mal og prover som anvender disse identifiserte genene eller gen-produktene
NO941485L (no)	1994-10-24	Fremgangsmåte for in vivo måling av konsentrasjonen av NMR-påviselig xenobiotisk forbindelse
Bhatt et al.	2014	Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice
MA33120B1 (fr)	2012-03-01	Procede ou systeme utilisant des biomarqueurs pour la surveillance d'un traitement